A Phase 4 interventional study of PRP group and Classic treatment in PRP Injection and Ulcer, sponsored by Hospital Mutua de Terrassa. Enrolling by invitation at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-12.
Sponsored by Hospital Mutua de Terrassa · Phase 4, Interventional, and Treatment
Treatment with platelet-rich plasma (PRP) consists of extracting a small amount of blood from the patient himself, which is later processed by centrifugation to obtain a fraction rich in platelets. It will be done on weekly or fortnightly blood extraction procedure, depending on the process. Between 1-3 sterile citrate collection tubes will be used, which may vary depending on the size of the ulcer. Each tube can contain approximately 8-10ml of blood and the procedure is carried out under aseptic conditions and with material from a single use Once the sample has been centrifuged, the blood plasma will be extracted and the concentrate obtained will be applied directly on the wound or ulcer with the objective of stimulating and accelerating healing by means of growth factors.
This procedure is used as complementary therapy in chronic ulcers or with difficulty in healing, such as they can be venous, arterial, pressure or diabetic foot ulcers.
Introduction
Platelet-rich plasma (PRP) is an autologous blood derivative obtained by centrifuging the patient's own blood. It contains a high concentration of growth factors that promote tissue regeneration and cell proliferation. Its use in the treatment of chronic ulcers has shown good results, especially in wounds that do not respond to conventional treatments.
Required Materials
Sterile 5 ml and 10 ml syringes
Needles or butterfly needle and 20G vacutainer for extraction, and 30G (4 mm or 13 mm) for infiltration
Tube with anticoagulant (3.8% sodium citrate), closed system technique
Clinical centrifuge with fixed-angle or swinging-bucket rotor
Gloves, mask, gown, and sterile working surface
Sterile dressings, saline solution, and antiseptics
Blood Extraction
Draw between 10 and 20 ml of venous blood from the patient, depending on the extent of the ulcer. Use tubes with anticoagulant to prevent premature coagulation.
Apply a closed system technique to avoid handling and contamination of the sample.
Centrifugation
Use a single centrifugation cycle to obtain high-quality PRP: 3500 rpm for 10 minutes.
Once the process is complete, prepare the PRP in the selected 5 ml or 10 ml syringes.
PRP Application
→ Before application:
Clean the wound with saline solution and antiseptic.
Perform debridement if there is necrotic or fibrinous tissue.
→ Application methods:
Intradermal or subdermal perilesional infiltration using a fine needle (30G 4 mm or 30G 13 mm).
Direct application of PRP onto the wound bed.
Apply a topical layer.
Cover with a sterile dressing or gauze soaked in the same PRP.
Monitoring and Follow-Up
Evaluate the wound weekly or biweekly.
Repeat treatment every 1-2 weeks depending on progress.
Take photographs and document each visit to assess clinical response.
Contraindications and Precautions
Severe thrombocytopenia (\< 100,000 platelets/μL)
Active systemic infection
Severe hematological disorders
Do not administer in case of allergy to the anticoagulants used
Active local infection
PRP represents an innovative and safe therapeutic option in the management of chronic ulcers, with good clinical outcomes and minimal side effects when performed using the appropriate technique.
Exclusion Criteria:
Group receiving treatment with PRP
Procedure: PRP group
Group receiving standard/traditional care
Procedure: Classic treatment
The PRP will be injected into the wound bed, unlike in other studies where it has been used only as a gel.
Standard care for patients in the control group: Aquacel + Gel every 48 hours
Change in ulcer diameter at 30, 60, and 90 days
Time frame: At the beginning of patient inclusion and at 30, 60, and 90 days from the start of therapy
Scoring on the PUSH Scale
The PUSH Scale assesses the area of the pressure ulcer (scored from 0 to 10), the amount of exudate (scored from 0 to 3), and the type of tissue (scored from 0 to 4). The higher the total score, the worse the condition of the ulcer
Time frame: At the beginning of the study, and at 30, 60, and 90 days from the start of the therapy
Amount of Exudate
Amount of ulcer exudate, scored from 0 to 3
Time frame: At the time of patient inclusion, and at 30, 60, and 92 days from the start of treatment
Plan to share: Yes — All patient data will be stored in the REDCAP system, which ensures the protection of patients' personal data.
Supporting information: Sap
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Mutua de Terrassa